Biotech Values

[DewDiligence]

> INSM – Like anything else, some docs do and others don't. That's not a comment on the science.<

I wasn’t commenting on the science—I was commenting on the business.

>…Iplex was beating Increlex in the market.<

INSM had a grand total of 130 patients.

As previously noted, I think you became over-involved emotionally in this stock. Your comment about executives going to jail is evidence of that, IMO.

I’m done on this topic. Have the last word if you want it. Good luck.